RVL Pharmaceuticals PLC
RVLP Healthcare Biotechnology
RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
Follow RVLP
RVL Pharmaceuticals PLC (RVLP) Piotroski F-score
RVL Pharmaceuticals PLC's Piotroski F-score for fiscal 2022 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2021.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 3 | 0.00 |
| FY2021 | 3 | (2.00) |
| FY2020 | 5 | 0.00 |
| FY2019 | 5 | 0.00 |
| FY2018 | 5 | — |
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (37.84%) | (25.18%) | Fail | 0 |
| Positive operating cash flow | (37.81m) | (54.73m) | Fail | 0 |
| Rising return on assets | (37.84%) | (25.18%) | Fail | 0 |
| Cash flow above net income | 13.88m | 10.19m | Pass | 1 |
| Falling long-term leverage | 0.41 | 0.17 | Fail | 0 |
| Rising current ratio | 2.89 | 2.95 | Fail | 0 |
| No new shares issued | 89,797,000 | 67,354,000 | Fail | 0 |
| Rising gross margin | 80.98% | 79.33% | Pass | 1 |
| Rising asset turnover | 0.36 | 0.07 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ADAPY Adaptimmune Therapeutics PLC compare | 4 |
| BCDA BioCardia, Inc. compare | 4 |
| DARE Dare Bioscience, Inc. compare | 4 |
| CLVSQ Clovis Oncology, Inc. compare | 3 |
| CNSY Cerenome, Inc. compare | 3 |
| RVLP RVL Pharmaceuticals PLC | 3 |
| TVRD Tvardi Therapeutics, Inc. compare | 3 |
| LPCN Lipocine Inc. compare | 1 |
| KTTA Pasithea Therapeutics Corp. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover